The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorChina-Japan Friendship Hospital

About this trial

The goal of this prospective, multi-centre, randomised controlled clinical study is to evaluate the diagnostic efficacy and safety of nCLE guided lung biopsy in patients with for peripheral lung nodules under the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS), and assess whether the biopsy techniques, namely transbronchial crybiopsy (TBCB) and transbronchial forceps biopsy (TBFB), would influence the diagnostic efficacy and safety of nCLE guided biopsy.

Participants will divided into nCLE-NB-rEBUS-forcep biopsy group, nCLE-NB-rEBUS-TBCB group, NB-rEBUS-forcep biopsy group, and NB-rEBUS-TBCB group at a 1:1:1:1 ratio by using central, computerized random sequence, and then undertake nCLE-NB-rEBUS-forcep biopsy, nCLE-NB-rEBUS-TBCB, NB-rEBUS-forcep biopsy, and NB-rEBUS-TBCB according to the group.

Researchers will compare the diagnostic yield and incidence of adverse events of the four biopsy techniques.

Eligibility criteria

Qualifiers

patients with peripheral lung nodules suspected of lung cancer based on CT scan (10mm≤size<30mm);

patients requiring diagnostic bronchoscopy procedure to determine the benign or malignant nature of the lung nodule;

Patients who can understand the purpose of the trial, participate voluntarily and sign an informed consent form.

Disqualifiers

Inability or non-willingness to provide informed consent;

Endobronchial visible malignancy on bronchoscopic inspection;

Target lesion within reach of the linear EBUS scope;

Failure to comply with the study protocol;

Trial design

Treatments tested in this trial

  • nCLE-NB-rEBUS-forcep biopsy
  • nCLE-NB-rEBUS-TBCB
  • NB-rEBUS-forcep biopsy
  • NB-rEBUS-TBCB

Treatment groups

1,040 Participants
are divided into 4 treatment groups